Your browser doesn't support javascript.
loading
Metabolic Alterations in Canine Mammary Tumors.
Tamarindo, Guilherme Henrique; Novais, Adriana Alonso; Chuffa, Luiz Gustavo Almeida; Zuccari, Debora Aparecida Pires Campos.
  • Tamarindo GH; Department of Molecular Biology, São José do Rio Preto Faculty of Medicine, São José do Rio Preto 15090-000, SP, Brazil.
  • Novais AA; Brazilian Biosciences National Laboratory, Brazilian Center for Research in Energy and Materials (CNPEM), Campinas 13083-970, SP, Brazil.
  • Chuffa LGA; Health Sciences Institute (ICS), Mato Grosso Federal University (UFMT), Sinop 78550-728, MT, Brazil.
  • Zuccari DAPC; Department of Structural and Functional Biology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu 18618-689, SP, Brazil.
Animals (Basel) ; 13(17)2023 Aug 30.
Article en En | MEDLINE | ID: mdl-37685021
ABSTRACT
Canine mammary tumors (CMTs) are among the most common diseases in female dogs and share similarities with human breast cancer, which makes these animals a model for comparative oncology studies. In these tumors, metabolic reprogramming is known as a hallmark of carcinogenesis whereby cells undergo adjustments to meet the high bioenergetic and biosynthetic demands of rapidly proliferating cells. However, such alterations are also vulnerabilities that may serve as a therapeutic strategy, which has mostly been tested in human clinical trials but is poorly explored in CMTs. In this dedicated review, we compiled the metabolic changes described for CMTs, emphasizing the metabolism of carbohydrates, amino acids, lipids, and mitochondrial functions. We observed key factors associated with the presence and aggressiveness of CMTs, such as an increase in glucose uptake followed by enhanced anaerobic glycolysis via the upregulation of glycolytic enzymes, changes in glutamine catabolism due to the overexpression of glutaminases, increased fatty acid oxidation, and distinct effects depending on lipid saturation, in addition to mitochondrial DNA, which is a hotspot for mutations. Therefore, more attention should be paid to this topic given that targeting metabolic fragilities could improve the outcome of CMTs.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article